Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kezar Life Sciences (KZR) Debt to Equity (2021 - 2025)

Kezar Life Sciences' Debt to Equity history spans 5 years, with the latest figure at $0.08 for Q3 2025.

  • For Q3 2025, Debt to Equity rose 4.74% year-over-year to $0.08; the TTM value through Sep 2025 reached $0.08, up 4.74%, while the annual FY2024 figure was $0.09, 64.56% up from the prior year.
  • Debt to Equity for Q3 2025 was $0.08 at Kezar Life Sciences, down from $0.09 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.09 in Q4 2024 and bottomed at $0.03 in Q2 2022.
  • The 5-year median for Debt to Equity is $0.05 (2021), against an average of $0.06.
  • The largest annual shift saw Debt to Equity fell 25.44% in 2022 before it surged 65.19% in 2024.
  • A 5-year view of Debt to Equity shows it stood at $0.05 in 2021, then dropped by 25.44% to $0.04 in 2022, then soared by 47.32% to $0.05 in 2023, then surged by 64.56% to $0.09 in 2024, then decreased by 9.23% to $0.08 in 2025.
  • Per Business Quant, the three most recent readings for KZR's Debt to Equity are $0.08 (Q3 2025), $0.09 (Q2 2025), and $0.09 (Q1 2025).